JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Strona główna・Stock List・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Closed

SectorHealthcare

Buy Sell

Overview

Share price change

24h

Current

Min

Max

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-0.05% downside

News Sentiment

By Acuity

68%

32%

315 / 352 Ranking in Healthcare

Mirati Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 23:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 lut 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 lut 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 lut 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 lut 2026, 23:38 UTC

Earnings

AMD Sales Climb on Help From Data-Center Business -- Update

3 lut 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 lut 2026, 23:27 UTC

Acquisitions, Mergers, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 lut 2026, 23:25 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 lut 2026, 23:22 UTC

Acquisitions, Mergers, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 lut 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 lut 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 lut 2026, 22:56 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 lut 2026, 22:40 UTC

Earnings

Amdocs Extends Collaboration With T-Mobile

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Adj EPS $1.81

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Rev $1.16B

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q EPS $1.45 >

3 lut 2026, 22:38 UTC

Earnings

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 lut 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 lut 2026, 22:14 UTC

Earnings

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 lut 2026, 22:13 UTC

Earnings

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 lut 2026, 22:12 UTC

Earnings

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 lut 2026, 22:10 UTC

Earnings

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 lut 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Comparison

Price change

Mirati Therapeutics Inc Forecast

Price Target

By TipRanks

-0.05% downside

12 Months Forecast

Average 58.67 USD -0.05%

High 59 USD

Low 58 USD

Based on 5 Wall Street analysts offering 12 month price targets forMirati Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Mirati Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

315 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.